📰 Previously Treated News
Page 3 - Previously Treated News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Previously Treated. Real-time updates on events, politics, business and more.
November 22, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...
November 14, 2022
Investegate announcements from AstraZeneca PLC, Enhertu recommended for EU approval in gastric
July 25, 2022
Investegate announcements from AstraZeneca PLC, Enhertu granted Priority Review for HER2-low mBC
February 8, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering...
February 8, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering...
November 4, 2021
/PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will...
November 4, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
August 11, 2021
Boston, MA (PRWEB) August 11, 2021 -- Boston, MA | August 11, 2021: CISCRP (Center for Information and Study on Clinical Research Participation) and Oxford
May 6, 2021
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program w...
January 18, 2021
previously treated HER2-positive advanced gastric cancer AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In the US, gastric cancer is most frequently diagnosed in t...